Desmedt et al. conducted the largest genomic study of ILC and found that mutations in PIK3CA (phosphatidylinositol, catalytic unit), HER and ESR1 (estrogen receptor 1) genes are more frequently present in ILC tumors that in other invasive breast cancers. This evidence concerns the gene ESR1 and invasive breast carcinoma.